Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Anesthesiology›Condition·Updated Jul 11, 2026·v1

Malignant Hyperthermia

Malignant hyperthermia is a rare pharmacogenetic emergency with high mortality if untreated. Immediate trigger removal, dantrolene administration, cooling, and correction of hyperkalemia are life‑saving. Definitive diagnosis via contracture testing or genetic analysis is essential for lifelong safe anesthetic planning.

High Evidence195 references·9,445 words·38 min read·v1
malignant hyperthermiadantroleneryanodine receptorRYR1anesthesiologyhypermetabolic crisismasseter spasmcaffeine-halothane contracture test

Quick Reference

RxDrug of choiceDantrolene 2.5 mg/kg IV, repeat every 5-10 min until crisis controlled; total dose often >10 mg/kg. Novel rapid formulation NPJ5008 is bioequivalent and 26-69% faster to prepare.
AltAlternativesAzumolene (investigational) - 2 mg/kg IV (animal data only). Cognitive aids (dynamic electronic checklists) improve dose accuracy.
⊘AvoidVolatile anesthetics (desflurane, sevoflurane, isoflurane, halothane), succinylcholine. Calcium channel blockers (verapamil, diltiazem) with dantrolene - risk of hyperkalemia. Serotonergic opioids (tramadol, meperidine, methadone) may mimic MH.
DxTest of choiceCaffeine‑halothane contracture test (IVCT/CHCT) - sensitivity >99%, specificity ~94%. Genetic testing (RYR1, CACNA1S, STAC3) - noninvasive but only 50-70% sensitivity.
ScKey scoreNorth American Malignant Hyperthermia Clinical Grading Scale (MH‑CGS) - score >35 indicates 'almost certain' MH (specificity 99%). Use retrospectively, not during crisis.
→When to referAfter acute MH event, refer to specialized MH testing center for contracture test and genetic counseling. Also refer first‑degree relatives for screening.
Speed is survival - every 10‑minute delay in dantrolene administration increases complication risk, reaching 100% at 50 minutes. Stock 36 vials immediately, prepare workstation with activated charcoal filters, and use TIVA or regional anesthesia for all susceptible patients.
Malignant hyperthermia (MH) is a rare, life-threatening pharmacogenetic hypermetabolic crisis triggered by volatile anesthetics (desflurane, sevoflurane, isoflurane, halothane) and succinylcholine. It arises from uncontrolled calcium release via the ryanodine receptor (RyR1) in skeletal muscle, leading to heat production, metabolic acidosis, rigidity, and multi-organ failure. Immediate recognition and treatment with dantrolene 2.5 mg/kg IV are critical; mortality without treatment exceeds 80%, but with prompt therapy it drops below 10%. Susceptibility is autosomal dominant with incomplete penetrance; prior uneventful anesthesia does not rule out risk. This overview covers background, evaluation, and acute management.

Overview and Recommendations

Background

  • •Malignant hyperthermia is a pharmacogenetic disorder of calcium homeostasis caused by gain‑of‑function mutations in the RYR1 gene (and rarely CACNA1S or STAC3), leading to uncontrolled sarcoplasmic reticulum calcium release upon exposure to volatile anesthetics or succinylcholine. The incidence is about 1.4 per 100,000 anesthetics, with a 5‑fold higher rate in children than adults. Mortality from desflurane‑associated MH is 25% in pharmacovigilance reports, highlighting the need for immediate action.
  • •The central molecular defect is a hypersensitive ryanodine receptor type 1 (RyR1) that opens persistently in the presence of triggering agents, producing a positive‑feedback loop of calcium overload. This drives continuous actin‑myosin cycling, ATP depletion, lactate production, and heat generation, the hypermetabolic crisis. Dantrolene, a selective RyR1 antagonist, stabilizes the channel in its closed conformation and is the only specific antidote.
  • •MH susceptibility is inherited in an autosomal dominant pattern; first‑degree relatives have a 50% risk of carrying the mutation. More than 400 RYR1 variants have been identified, with at least 34 definitively causal. Penetrance is incomplete, only 40.6% of mutation carriers develop MH on exposure, and prior uneventful anesthesia does not exclude susceptibility.
  • •Beyond the operating room, RYR1 mutations predispose to exertional heat illness, rhabdomyolysis, and even awake MH triggered by exercise or heat. The same molecular pathway (RyR → mitochondrial reactive oxygen species) also contributes to chronic pain states, linking MH to neuropathic pain mechanisms. Understanding this paradigm is essential for recognizing atypical presentations.

Evaluation

  • •Suspect MH in any patient receiving volatile anesthetics or succinylcholine who develops an unexplained rise in end‑tidal CO₂ (ETCO₂ >55 mmHg) despite increased minute ventilation. This is often the earliest sign, preceding hyperthermia by minutes.
  • •Examine for sinus tachycardia, tachypnea, and generalized muscle rigidity, especially masseter spasm after succinylcholine. In children, rigidity is the most common initial sign; in adolescents, tachycardia and hypercarbia dominate. Temperature rise is a late sign; once present, core temperature can increase >0.5°C every 15 minutes.
  • •Assess vital signs continuously: hyperdynamic state initially, then hypotension and arrhythmias as metabolic acidosis and hyperkalemia progress. Check ECG for peaked T waves (hyperkalemia) and widened QRS. Obtain arterial blood gas to confirm mixed respiratory/metabolic acidosis (pH <7.25, PaCO₂ >60 mmHg).
  • •Order serum chemistry immediately: potassium, creatine kinase (CK), blood glucose, and lactate. CK often exceeds 10,000 U/L; hyperglycemia can be an early sign. Urine dipstick positive for blood without red cells suggests myoglobinuria. Rapidly rising potassium >6.0 mmol/L is a critical threshold requiring urgent treatment.
  • •The North American Malignant Hyperthermia Clinical Grading Scale (MH‑CGS) assigns points to seven domains (rigidity, hyperthermia, acidosis, respiratory, cardiac, laboratory, rapid onset). A score >35 indicates 'almost certain' MH with 99% specificity. However, treatment must never be delayed to calculate a score; use it retrospectively for documentation.
  • •After the acute event, definitive diagnosis requires referral to a specialized center for caffeine‑halothane contracture testing (CHCT) or genetic testing (RYR1, CACNA1S, STAC3). CHCT has sensitivity >99% and specificity ~94%. Genetic testing is noninvasive but detects only 50‑70% of cases; a negative result does not exclude susceptibility.
  • •Differential diagnoses include serotonin toxicity (especially with meperidine, tramadol, or fentanyl), thyroid storm, pheochromocytoma, sepsis, and neuroleptic malignant syndrome. Drug history and timing relative to anesthetic exposure help distinguish these mimics. Serotonin toxicity shares hyperthermia, rigidity, and autonomic instability but responds to cyproheptadine, not dantrolene.

Management

  • •Immediately discontinue all volatile anesthetics and succinylcholine. Switch to propofol‑based total intravenous anesthesia (TIVA). Hyperventilate with 100% oxygen at flows >10 L/min to wash out residual agent and correct hypercapnia. Call for help and activate the institutional MH response team; deploy a cognitive aid checklist.
  • •Administer dantrolene 2.5 mg/kg intravenously as rapidly as possible. Reconstitute each 20 mg vial with 60 mL sterile water (no preservative) by vigorous shaking until clear. Repeat 2.5 mg/kg every 5‑10 minutes until signs of hypermetabolism resolve (declining ETCO₂, decreasing heart rate, resolving rigidity). Total doses may exceed 10 mg/kg in fulminant cases.
  • •Stock a minimum of 36 vials (720 mg) immediately available and an additional 24 vials (480 mg) obtainable within 1 hour wherever volatile agents or succinylcholine are used. In ambulatory surgery centers, this stocking is cost‑effective (ICER $196,320 per life saved). The novel rapid‑preparation formulation NPJ5008 is bioequivalent and 26‑69% faster to prepare.
  • •Begin active cooling: apply ice packs to groin, axillae, and neck; use a cooling blanket; infuse cold (4°C) intravenous crystalloid (balanced solution, not 0.9% saline). Stop cooling once core temperature falls below 38.5°C to avoid overshoot hypothermia.
  • •Treat hyperkalemia (K⁺ >6.0 mmol/L) with calcium gluconate 10‑30 mg/kg IV, then insulin 0.1 U/kg with dextrose 0.5 g/kg, and sodium bicarbonate 1‑2 mEq/kg only if pH <7.1. Avoid sodium bicarbonate if pH >7.1 as it may worsen intracellular acidosis.
  • •Manage hypotension with IV fluids initially; if refractory, use epinephrine (dose‑titrated). Avoid calcium channel blockers (verapamil, diltiazem) because they can precipitate life‑threatening hyperkalemia when combined with dantrolene. Treat arrhythmias per ACLS guidelines once hyperkalemia and hyperthermia are addressed.
  • •Transfer the patient to the intensive care unit for at least 24 hours of continuous monitoring. Recrudescence occurs in 14.4% of cases; continue dantrolene 1 mg/kg every 6 hours for 24‑48 hours after initial crisis control. Monitor CK, potassium, core temperature, and arterial blood gases every 4‑6 hours until stable.
  • •Do NOT discontinue dantrolene prematurely; recrudescence can be fatal. Do NOT use oral dantrolene prophylactically before elective surgery in known MH‑susceptible patients, it is not indicated. Do NOT use non‑dihydropyridine calcium channel blockers (diltiazem, verapamil) during or after an MH crisis.
  • •Refer the patient and first‑degree relatives to a specialized MH testing center for confirmatory contracture testing and genetic counseling. Flag the medical record prominently and advise the patient to wear a MedicAlert bracelet. Educate that susceptibility is lifelong and all future anesthetics require trigger‑free planning.
  • •For MH‑susceptible patients undergoing elective surgery, use total intravenous anesthesia (propofol + opioid) or regional anesthesia (neuraxial blocks, peripheral nerve blocks) to eliminate exposure to volatiles and succinylcholine. Prepare the anesthesia workstation with activated charcoal filters on inspiratory and expiratory limbs to decontaminate in <2 minutes.
  • •In class B ambulatory facilities without dantrolene, the SAMBA 2017 position states that succinylcholine may be used for emergency airway rescue if laryngospasm risk outweighs MH risk, but MHAUS recommends against it. If succinylcholine is used, prepare for immediate transfer to a facility with dantrolene. The rocuronium‑sugammadex combination is a safer alternative.
  • •Prognosis: mortality with modern treatment is 1‑10%, with higher risk in older adults (14.1%) and lower in children (0.7%). Treatment delay increases complications by 100% every 30 minutes. After a 50‑minute delay, complications are nearly universal. Early dantrolene and aggressive supportive care are the keys to survival.

Board Review — High Yield

  • •ETCO₂ >55 mmHg - earliest sign of MH; hyperventilate with 100% O₂ immediately.
  • •Dantrolene 2.5 mg/kg IV - first‑line therapy; repeat every 5‑10 min; total dose may exceed 10 mg/kg.
  • •Masseter spasm after succinylcholine - classic red flag, especially in children 2‑12 years; proceed with dantrolene.
  • •Prior uneventful anesthesia does not rule out susceptibility - 13.2% of probands had previous unremarkable exposure.
  • •Mortality reduced from >80% to <10% with dantrolene introduction (1980s).
  • •RYR1 autosomal dominant - first‑degree relatives have 50% risk; more than 400 variants known.
  • •Avoid calcium channel blockers with dantrolene - can cause life‑threatening hyperkalemia and myocardial depression.
  • •Activated charcoal filters decontaminate workstation in <2 min (vs 88 min without).
  • •Recrudescence in ~14% - continue dantrolene for 24‑48 h after crisis; may be fatal if not recognized.
  • •Children <12 years have lower mortality (0.7%) than adults (14.1%) but present with rigidity and fever more often than hypercarbia.

Deep Dive — Evidence Details

References

  1. [1]

    Godai K, Takahashi K, Kashiwagi Y et al.. “Ryanodine Receptor to Mitochondrial Reactive Oxygen Species Pathway Plays an Important Role in Chronic Human Immunodeficiency Virus gp120MN-Induced Neuropathic Pain in Rats.” Anesthesia and analgesia (2019). PMID: 30507840 ↗

    L5OTHERCited in: Definition, Classification and Pain Phenotype, Pathophysiology and Mechanism
  2. [2]

    Wei W, Chen L, Ying X. “Desflurane Safety Revisited: A Pharmacovigilance Study Detecting Potential Safety Signals from FAERS Data.” Journal of pain research (2025). PMID: 41041661 ↗

    L4OTHERCited in: Definition, Classification and Pain Phenotype, Prevention, Screening and Surveillance
  3. [3]

    Wang CX, Kale N, Wu VJ et al.. “Age, female sex, and oral contraceptive use are risk factors for anterior cruciate ligament reconstruction: A nationwide database study.” The Knee (2022). PMID: 36434970 ↗

    L2OTHERCited in: Definition, Classification and Pain Phenotype
  4. [4]

    Ibarra Moreno CA, Silva HCA, Voermans NC et al.. “Myopathic manifestations across the adult lifespan of patients with malignant hyperthermia susceptibility: a narrative review.” British journal of anaesthesia (2024). PMID: 39107166 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation
  5. [5]

    Lerman J. “Perioperative management of the paediatric patient with coexisting neuromuscular disease.” British journal of anaesthesia (2011). PMID: 22156273 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, Special Populations and Pregnancy
  6. [6]

    Parness J, Bandschapp O, Girard T. “The myotonias and susceptibility to malignant hyperthermia.” Anesthesia and analgesia (2009). PMID: 19762732 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Severity, Staging and Perioperative Risk Stratification, Acute Management and Crisis Pathways, Complications
  7. [7]

    Capacchione JF, Muldoon SM. “The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia.” Anesthesia and analgesia (2009). PMID: 19617585 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Severity, Staging and Perioperative Risk Stratification, Acute Management and Crisis Pathways
  8. [8]

    Thompson SJ, Riazi S, Kraeva N et al.. “Skeletal Muscle Metabolic Dysfunction in Patients With Malignant Hyperthermia Susceptibility.” Anesthesia and analgesia (2017). PMID: 28682948 ↗

    L4OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup
  9. [9]

    Gwak M, Park P, Kim K et al.. “The effects of dantrolene on hypoxic-ischemic injury in the neonatal rat brain.” Anesthesia and analgesia (2008). PMID: 18165582 ↗

    L5OTHERCited in: Pathophysiology and Mechanism
  10. [10]

    Kobayashi S, Wakeyama T, Ono S et al.. “A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design.” Journal of cardiology (2019). PMID: 31866190 ↗

    L5TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Prognosis and Natural History
  11. [11]

    Al-Kuraishy HM, Mohammed HA, Sulaiman GM et al.. “Targeting of inflammation and prostaglandins by nonsteroidal anti-inflammatory drugs in schizophrenia: A narrative review.” Psychiatry research (2025). PMID: 40472596 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Multimodal Analgesia Ladder and Long-term Pharmacotherapy
  12. [12]

    Pinyavat T, Riazi S, Deng J et al.. “Malignant Hyperthermia.” Critical care medicine (2024). PMID: 39171998 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  13. [13]

    Kaye AD, Koress CM, Novitch MB et al.. “Pharmacogenomics, concepts for the future of perioperative medicine and pain management: A review.” Best practice & research. Clinical anaesthesiology (2020). PMID: 33004174 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Multimodal Analgesia Ladder and Long-term Pharmacotherapy
  14. [14]

    Laitano O, Murray KO, Leon LR. “Overlapping Mechanisms of Exertional Heat Stroke and Malignant Hyperthermia: Evidence vs. Conjecture.” Sports medicine (Auckland, N.Z.) (2020). PMID: 32632746 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  15. [15]

    Laitano O, Leon LR, Roberts WO et al.. “Controversies in exertional heat stroke diagnosis, prevention, and treatment.” Journal of applied physiology (Bethesda, Md. : 1985) (2019). PMID: 31545156 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Multimodal Analgesia Ladder and Long-term Pharmacotherapy
  16. [16]

    Rosenberg H, Pollock N, Schiemann A et al.. “Malignant hyperthermia: a review.” Orphanet journal of rare diseases (2015). PMID: 26238698 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  17. [17]

    McAllen KJ, Schwartz DR. “Adverse drug reactions resulting in hyperthermia in the intensive care unit.” Critical care medicine (2010). PMID: 20502177 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  18. [18]

    Hopkins PM, Girard T, Dalay S et al.. “Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists.” Anaesthesia (2021). PMID: 33399225 ↗

    L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment, Complications
  19. [19]

    Urman RD, Rajan N, Belani K et al.. “Malignant Hyperthermia-Susceptible Adult Patient and Ambulatory Surgery Center: Society for Ambulatory Anesthesia and Ambulatory Surgical Care Committee of the American Society of Anesthesiologists Position Statement.” Anesthesia and analgesia (2019). PMID: 31166228 ↗

    L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity, Staging and Perioperative Risk Stratification, Acute Management and Crisis Pathways, History and Evolution of Treatment, Complications, Prognosis and Natural History
  20. [20]

    Ibarra Moreno CA, Hu S, Kraeva N et al.. “An Assessment of Penetrance and Clinical Expression of Malignant Hyperthermia in Individuals Carrying Diagnostic Ryanodine Receptor 1 Gene Mutations.” Anesthesiology (2019). PMID: 31206373 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Perioperative Risk Stratification, Special Populations and Pregnancy
  21. [21]

    Sato K, Roesl C, Pollock N et al.. “Skeletal muscle ryanodine receptor mutations associated with malignant hyperthermia showed enhanced intensity and sensitivity to triggering drugs when expressed in human embryonic kidney cells.” Anesthesiology (2013). PMID: 23459219 ↗

    L5OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup
  22. [22]

    Rosero EB, Adesanya AO, Timaran CH et al.. “Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005.” Anesthesiology (2009). PMID: 19104175 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Prognosis and Natural History, Special Populations and Pregnancy
  23. [23]

    Sumitani M, Uchida K, Yasunaga H et al.. “Prevalence of malignant hyperthermia and relationship with anesthetics in Japan: data from the diagnosis procedure combination database.” Anesthesiology (2011). PMID: 21169796 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, Acute Management and Crisis Pathways, Special Populations and Pregnancy
  24. [24]

    Aderibigbe T, Lang BH, Rosenberg H et al.. “Cost-effectiveness analysis of stocking dantrolene in ambulatory surgery centers for the treatment of malignant hyperthermia.” Anesthesiology (2014). PMID: 24714119 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, Acute Management and Crisis Pathways, Prognosis and Natural History
  25. [25]

    Ho PT, Carvalho B, Sun EC et al.. “Cost-benefit Analysis of Maintaining a Fully Stocked Malignant Hyperthermia Cart versus an Initial Dantrolene Treatment Dose for Maternity Units.” Anesthesiology (2018). PMID: 29672336 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Prognosis and Natural History, Special Populations and Pregnancy
  26. [26]

    Malandrini A, Orrico A, Gaudiano C et al.. “Muscle biopsy and in vitro contracture test in subjects with idiopathic HyperCKemia.” Anesthesiology (2008). PMID: 18813041 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup
  27. [27]

    Figueroa L, Kraeva N, Manno C et al.. “Distinct pathophysiological characteristics in developing muscle from patients susceptible to malignant hyperthermia.” British journal of anaesthesia (2023). PMID: 36792386 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors
  28. [28]

    Regueiro M, Siegmund B, Horst S et al.. “Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis.” Inflammatory bowel diseases (2025). PMID: 39018016 ↗

    L2RCTCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Multimodal Analgesia Ladder and Long-term Pharmacotherapy
  29. [29]

    Pai SL, Grech D, Gayer S et al.. “Should rocuronium and sugammadex replace succinylcholine for airway emergencies in class B ambulatory anesthesia settings?” Minerva anestesiologica (2022). PMID: 36326774 ↗

    L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Crisis Pathways
  30. [30]

    Patton K, Borshoff DC. “Adverse drug reactions.” Anaesthesia (2018). PMID: 29313907 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Perioperative Risk Stratification, Acute Management and Crisis Pathways
  31. [31]

    Gurnaney H, Brown A, Litman RS. “Malignant hyperthermia and muscular dystrophies.” Anesthesia and analgesia (2009). PMID: 19762730 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Severity, Staging and Perioperative Risk Stratification, Acute Management and Crisis Pathways, Complications, Special Populations and Pregnancy
  32. [32]

    Benca J, Hogan K. “Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options.” Anesthesia and analgesia (2009). PMID: 19762731 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Severity, Staging and Perioperative Risk Stratification, Acute Management and Crisis Pathways, Complications
  33. [33]

    Klingler W, Rueffert H, Lehmann-Horn F et al.. “Core myopathies and risk of malignant hyperthermia.” Anesthesia and analgesia (2009). PMID: 19762745 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Severity, Staging and Perioperative Risk Stratification, Acute Management and Crisis Pathways, Complications
  34. [34]

    Otsuki S, Miyoshi H, Mukaida K et al.. “Age-Specific Clinical Features of Pediatric Malignant Hyperthermia: A Review of 187 Cases Over 60 Years in Japan.” Anesthesia and analgesia (2021). PMID: 34962895 ↗

    L4REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Special Populations and Pregnancy
  35. [35]

    McEvoy MD, Thies KC, Einav S et al.. “Cardiac Arrest in the Operating Room: Part 2-Special Situations in the Perioperative Period.” Anesthesia and analgesia (2018). PMID: 29200065 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management and Crisis Pathways
  36. [36]

    Nelson P, Litman RS. “Malignant hyperthermia in children: an analysis of the North American malignant hyperthermia registry.” Anesthesia and analgesia (2014). PMID: 24299931 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Acute Management and Crisis Pathways, History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Pregnancy
  37. [37]

    Riazi S, Larach MG, Hu C et al.. “Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands.” Anesthesia and analgesia (2014). PMID: 23842196 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Special Populations and Pregnancy
  38. [38]

    Brady JE, Sun LS, Rosenberg H et al.. “Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005.” Anesthesia and analgesia (2009). PMID: 19762744 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors
  39. [39]

    Lu Z, Rosenberg H, Brady JE et al.. “Prevalence of Malignant Hyperthermia Diagnosis in New York State Ambulatory Surgery Center Discharge Records 2002 to 2011.” Anesthesia and analgesia (2016). PMID: 26554462 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors
  40. [40]

    Tellor Pennington BR, Janda AM, Colquhoun DA et al.. “Trajectories of Recovery after Intravenous propofol versus inhaled VolatilE anaesthesia (THRIVE) randomised controlled trial in the USA: A protocol.” BMJ open (2025). PMID: 40953862 ↗

    L5TRIAL_NONRANDOMCited in: Epidemiology, Etiology and Risk Factors, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  41. [41]

    Ye X, Zeng Y, Zhang H et al.. “Development and Validation of a Predictive Model for Hypoxemia in the Postanesthesia Care Unit Following Thoracoscopic Lung Surgery: A Multicenter Cohort Study.” Journal of cardiothoracic and vascular anesthesia (2025). PMID: 41130848 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity, Staging and Perioperative Risk Stratification, History and Evolution of Treatment, Complications, Special Populations and Pregnancy
  42. [42]

    Hazarika H, Saxena A, Meshram P et al.. “A randomized controlled trial comparing C Mac D Blade and Macintosh laryngoscope for nasotracheal intubation in patients undergoing surgeries for head and neck cancer.” Saudi journal of anaesthesia (2018). PMID: 29416454 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Perioperative Risk Stratification
  43. [43]

    In J, Ahn EJ, Lee DK et al.. “Incidence of malignant hyperthermia in patients undergoing general anesthesia: Protocol for a systematic review and meta-analysis.” Medicine (2017). PMID: 29245345 ↗

    L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, Acute Management and Crisis Pathways
  44. [44]

    He J, Luo X, Li C et al.. “Investigation into neuroleptic malignant syndrome triggered by atypical antipsychotics: Insights from FDA adverse event reporting system database.” Journal of affective disorders (2025). PMID: 40419159 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors
  45. [45]

    Frassanito L, Sbaraglia F, Piersanti A et al.. “Real Evidence and Misconceptions about Malignant Hyperthermia in Children: A Narrative Review.” Journal of clinical medicine (2023). PMID: 37373564 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
  46. [46]

    Riazi S, Bersselaar LRVD, Islander G et al.. “Pre-operative exercise and pyrexia as modifying factors in malignant hyperthermia (MH).” Neuromuscular disorders : NMD (2022). PMID: 35738978 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors
  47. [47]

    Larach MG, Klumpner TT, Brandom BW et al.. “Succinylcholine Use and Dantrolene Availability for Malignant Hyperthermia Treatment: Database Analyses and Systematic Review.” Anesthesiology (2019). PMID: 30550426 ↗

    L2SR_OBSCited in: Clinical Presentation, Acute Management and Crisis Pathways, Complications
  48. [48]

    Rüffert H, Gillies R, Hopkins PM et al.. “European Malignant Hyperthermia Group 2025 guidelines for the investigation of malignant hyperthermia susceptibility.” British journal of anaesthesia (2026). PMID: 41478797 ↗

    L1GUIDELINECited in: Clinical Presentation, History and Evolution of Treatment, Complications
  49. [49]

    Rüffert H, Bastian B, Bendixen D et al.. “Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group.” British journal of anaesthesia (2020). PMID: 33131754 ↗

    L1GUIDELINECited in: Clinical Presentation, History and Evolution of Treatment, Regional and Interventional Procedures, Complications
  50. [50]

    Hopkins PM, Rüffert H, Snoeck MM et al.. “European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility.” British journal of anaesthesia (2015). PMID: 26188342 ↗

    L1GUIDELINECited in: Clinical Presentation, History and Evolution of Treatment, Complications
  51. [51]

    Glahn KPE, Bendixen D, Girard T et al.. “Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines.” British journal of anaesthesia (2020). PMID: 32591088 ↗

    L1GUIDELINECited in: Clinical Presentation, Acute Management and Crisis Pathways, History and Evolution of Treatment, Complications
  52. [52]

    Glahn KP, Ellis FR, Halsall PJ et al.. “Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group.” British journal of anaesthesia (2010). PMID: 20837722 ↗

    L1GUIDELINECited in: Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment, Complications
  53. [53]

    Riazi S, Watt S, Plester J et al.. “A Proposed North American Approach for Genetic Testing of Individuals at Risk for Malignant Hyperthermia.” Anesthesiology (2026). PMID: 41805301 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Severity, Staging and Perioperative Risk Stratification, History and Evolution of Treatment, Complications
  54. [54]

    Biesecker LG, Dirksen RT, Girard T et al.. “Genomic Screening for Malignant Hyperthermia Susceptibility.” Anesthesiology (2020). PMID: 32898259 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Complications
  55. [55]

    Riazi S, Kraeva N, Hopkins PM. “Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.” Anesthesiology (2018). PMID: 28902675 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, Acute Management and Crisis Pathways, Complications
  56. [56]

    Hopkins PM. “Malignant hyperthermia: pharmacology of triggering.” British journal of anaesthesia (2011). PMID: 21624965 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  57. [57]

    Baldo BA, Rose MA. “The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review.” British journal of anaesthesia (2019). PMID: 31653394 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Multimodal Analgesia Ladder and Long-term Pharmacotherapy
  58. [58]

    Stowell KM. “DNA testing for malignant hyperthermia: the reality and the dream.” Anesthesia and analgesia (2014). PMID: 24445638 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Complications
  59. [59]

    Hirshey Dirksen SJ, Larach MG, Rosenberg H et al.. “Special article: Future directions in malignant hyperthermia research and patient care.” Anesthesia and analgesia (2011). PMID: 21709147 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Complications
  60. [60]

    Saidman LJ. “Serendipity: Being in the Right Place at the Right Time.” Anesthesiology (2022). PMID: 35180293 ↗

    L5OTHERCited in: Clinical Presentation, Complications
  61. [61]

    Yu KD, Betts MN, Urban GM et al.. “Evaluation of Malignant Hyperthermia Features in Patients with Pathogenic or Likely Pathogenic RYR1 Variants Disclosed through a Population Genomic Screening Program.” Anesthesiology (2024). PMID: 37787745 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup
  62. [62]

    Timmins MA, Rosenberg H, Larach MG et al.. “Malignant hyperthermia testing in probands without adverse anesthetic reaction.” Anesthesiology (2015). PMID: 26068069 ↗

    L4OTHERCited in: Clinical Presentation, Complications, Special Populations and Pregnancy
  63. [63]

    Yang T, Riehl J, Esteve E et al.. “Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse.” Anesthesiology (2006). PMID: 17122579 ↗

    L5OTHERCited in: Clinical Presentation, Diagnosis and Workup, Complications
  64. [64]

    Miller DM, Daly C, Aboelsaod EM et al.. “Genetic epidemiology of malignant hyperthermia in the UK.” British journal of anaesthesia (2018). PMID: 30236257 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Complications
  65. [65]

    Hopkins PM. “What is malignant hyperthermia susceptibility?” British journal of anaesthesia (2023). PMID: 37198032 ↗

    L5OTHERCited in: Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment, Complications
  66. [66]

    O'Neill SS, Smurthwaite GJ. “Malignant hyperthermia presenting during laparoscopic adrenalectomy.” Anaesthesia (2008). PMID: 18412655 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup, Complications
  67. [67]

    Russell T, Riazi S, Kraeva N et al.. “Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene.” Anaesthesia (2012). PMID: 22734812 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup
  68. [68]

    Xu ZH, Luo AL, Guo XY et al.. “Malignant hyperthermia in China.” Anesthesia and analgesia (2006). PMID: 17000816 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, Acute Management and Crisis Pathways, Complications
  69. [69]

    Ginsberg M, Michelson M, Aharoni S et al.. “The Clinical, Histological, and Genetic Spectrum of RYR1 Variants-A Multi-Center Israeli Cohort Study.” Journal of clinical medicine (2026). PMID: 41753076 ↗

    L4COHORTCited in: Clinical Presentation, Severity, Staging and Perioperative Risk Stratification
  70. [70]

    Tsutsumi YM, Nagasaka H, Mukaida K et al.. “JSA guideline for management of malignant hyperthermia in 2025.” Journal of anesthesia (2026). PMID: 41504952 ↗

    L1GUIDELINECited in: Clinical Presentation, History and Evolution of Treatment, Complications
  71. [71]

    Schuster F, Gardill A, Metterlein T et al.. “A minimally invasive metabolic test with intramuscular injection of halothane 5 and 6 vol% to detect probands at risk for malignant hyperthermia.” Anaesthesia (2007). PMID: 17697213 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis and Workup, Complications
  72. [72]

    Hoppe K, Schleip R, Lehmann-Horn F et al.. “Contractile elements in muscular fascial tissue - implications for in-vitro contracture testing for malignant hyperthermia.” Anaesthesia (2014). PMID: 24909539 ↗

    L5OTHERCited in: Clinical Presentation, Diagnosis and Workup, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, Acute Management and Crisis Pathways, Complications
  73. [73]

    Jerath A, Slessarev M, Martin C et al.. “Sedating with volatile anaesthetics for COVID-19 and non-COVID-19 acute hypoxaemic respiratory failure patients in ICU (SAVE-ICU): protocol for a randomised clinical trial.” BMJ open (2025). PMID: 41083292 ↗

    L5TRIAL_NONRANDOMCited in: Clinical Presentation, Severity, Staging and Perioperative Risk Stratification, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, History and Evolution of Treatment
  74. [74]

    Sun HJ, Chia YY, Huang YY et al.. “Hyperglycemia as an atypical finding of malignant hyperthermia: A case report and literature review.” Journal of diabetes investigation (2025). PMID: 40607996 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Complications
  75. [75]

    Riazi S, Watt S, Plester J et al.. “A proposed North American approach for genetic testing of individuals at risk for malignant hyperthermia.” Canadian journal of anaesthesia = Journal canadien d'anesthesie (2026). PMID: 42189464 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment
  76. [76]

    Maino A, Dehaen-Rougelin C, Dalmas-Laurent AF et al.. “Identification of a novel de novo RYR1 variant associated with malignant hyperthermia : A case report.” European journal of anaesthesiology (2025). PMID: 41017341 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Acute Management and Crisis Pathways, Complications
  77. [77]

    Limper U, Ströhlein M, Harth A et al.. “Impaired renal graft perfusion due to malignant hyperthermia in kidney transplantation: early reduced graft perfusion by Doppler ultrasonography.” British journal of anaesthesia (2025). PMID: 40992998 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup, Complications
  78. [78]

    Ajetunmobi O, Wong D, Perlas A et al.. “Impact of Sugammadex Versus Neostigmine Reversal on Postoperative Recovery Time in Patients With Obstructive Sleep Apnea Undergoing Bariatric Surgery: A Double-Blind, Randomized Controlled Trial.” Anesthesia and analgesia (2024). PMID: 38848257 ↗

    L1RCTCited in: Diagnosis and Workup, History and Evolution of Treatment, Multimodal Analgesia Ladder and Long-term Pharmacotherapy, Prognosis and Natural History, Special Populations and Pregnancy
  79. [79]

    Footitt EJ, Sinha MD, Raiman JA et al.. “Mitochondrial disorders and general anaesthesia: a case series and review.” British journal of anaesthesia (2008). PMID: 18285393 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, Acute Management and Crisis Pathways, Complications, Special Populations and Pregnancy
  80. [80]

    Pinyavat T, Rosenberg H, Lang BH et al.. “Accuracy of malignant hyperthermia diagnoses in hospital discharge records.” Anesthesiology (2015). PMID: 25272246 ↗

    L4OTHERCited in: Diagnosis and Workup, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, History and Evolution of Treatment, Complications, Special Populations and Pregnancy
  81. [81]

    Gonsalves SG, Ng D, Johnston JJ et al.. “Using exome data to identify malignant hyperthermia susceptibility mutations.” Anesthesiology (2013). PMID: 24195946 ↗

    L4OTHERCited in: Diagnosis and Workup, Special Populations and Pregnancy
  82. [82]

    Singh DP, Perry MJ, Bjorksten AR et al.. “Single Muscle Fiber Calcium Wave Frequency Assay for Malignant Hyperthermia Diagnosis: An Exploratory Validation Study.” Anesthesiology (2025). PMID: 41349013 ↗

    L4OTHERCited in: Diagnosis and Workup
  83. [83]

    Bina S, Cowan G, Karaian J et al.. “Effects of caffeine, halothane, and 4-chloro-m-cresol on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.” Anesthesiology (2006). PMID: 16394695 ↗

    L5OTHERCited in: Diagnosis and Workup, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  84. [84]

    Johannsen S, Türkmeneli I, Isbary S et al.. “Ultrasound Elastography for Rapid, Real-time Detection of Localized Muscular Reaction in Malignant Hyperthermia-susceptible Pigs.” Anesthesiology (2018). PMID: 30204593 ↗

    L5OTHERCited in: Diagnosis and Workup
  85. [85]

    Merritt A, Booms P, Shaw MA et al.. “Assessing the pathogenicity of RYR1 variants in malignant hyperthermia.” British journal of anaesthesia (2017). PMID: 28403410 ↗

    L4OTHERCited in: Diagnosis and Workup
  86. [86]

    Chang L, Daly C, Miller DM et al.. “Permeabilised skeletal muscle reveals mitochondrial deficiency in malignant hyperthermia-susceptible individuals.” British journal of anaesthesia (2019). PMID: 30916033 ↗

    L3OTHERCited in: Diagnosis and Workup, Special Populations and Pregnancy
  87. [87]

    Schiemann AH, Stowell KM. “Comparison of pathogenicity prediction tools on missense variants in RYR1 and CACNA1S associated with malignant hyperthermia.” British journal of anaesthesia (2016). PMID: 27147545 ↗

    L5OTHERCited in: Diagnosis and Workup
  88. [88]

    Yousef MA, Vaida S, Somri M et al.. “Changes in creatine phosphokinase (CK) concentrations after minor and major surgeries in children.” British journal of anaesthesia (2006). PMID: 16595613 ↗

    L2OTHERCited in: Diagnosis and Workup, Special Populations and Pregnancy
  89. [89]

    Kruijt N, van den Bersselaar LR, Wijma J et al.. “HyperCKemia and rhabdomyolysis in the neuroleptic malignant and serotonin syndromes: A literature review.” Neuromuscular disorders : NMD (2020). PMID: 33250373 ↗

    L4SR_OBSCited in: Diagnosis and Workup
  90. [90]

    Litman RS, Smith VI, Larach MG et al.. “Consensus Statement of the Malignant Hyperthermia Association of the United States on Unresolved Clinical Questions Concerning the Management of Patients With Malignant Hyperthermia.” Anesthesia and analgesia (2019). PMID: 30768455 ↗

    L5OTHERCited in: Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History
  91. [91]

    Gleich SJ, Tien M, Schroeder DR et al.. “Anesthetic Outcomes of Children With Arthrogryposis Syndromes: No Evidence of Hyperthermia.” Anesthesia and analgesia (2017). PMID: 28099287 ↗

    L2OTHERCited in: Diagnosis and Workup, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, Acute Management and Crisis Pathways, Prognosis and Natural History, Special Populations and Pregnancy
  92. [92]

    Brandom BW, Larach MG, Chen MS et al.. “Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States.” Anesthesia and analgesia (2011). PMID: 21372281 ↗

    L4OTHERCited in: Diagnosis and Workup, Severity, Staging and Perioperative Risk Stratification, Prognosis and Natural History
  93. [93]

    Vukcevic M, Broman M, Islander G et al.. “Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease.” Anesthesia and analgesia (2010). PMID: 20142353 ↗

    L4OTHERCited in: Diagnosis and Workup
  94. [94]

    Larach MG, Brandom BW, Allen GC et al.. “Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States.” Anesthesia and analgesia (2014). PMID: 25268394 ↗

    L4OTHERCited in: Diagnosis and Workup, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  95. [95]

    Schuster F, Metterlein T, Negele S et al.. “An in-vivo metabolic test for detecting malignant hyperthermia susceptibility in humans: a pilot study.” Anesthesia and analgesia (2008). PMID: 18713904 ↗

    L3OTHERCited in: Diagnosis and Workup
  96. [96]

    Metterlein T, Schuster F, Kranke P et al.. “Magnesium does not influence the clinical course of succinylcholine-induced malignant hyperthermia.” Anesthesia and analgesia (2011). PMID: 21474662 ↗

    L5OTHERCited in: Diagnosis and Workup, Prognosis and Natural History
  97. [97]

    Finsterer J, Scorza FA, Scorza CA. “Significance of Asymptomatic Hyper Creatine-Kinase Emia.” Journal of clinical neuromuscular disease (2019). PMID: 31743252 ↗

    L5SR_OBSCited in: Diagnosis and Workup, Prevention, Screening and Surveillance
  98. [98]

    Haverfield EV, Esplin ED, Aguilar SJ et al.. “Physician-directed genetic screening to evaluate personal risk for medically actionable disorders: a large multi-center cohort study.” BMC medicine (2021). PMID: 34404389 ↗

    L2COHORTCited in: Diagnosis and Workup, Severity, Staging and Perioperative Risk Stratification
  99. [99]

    Wadhwani AR, Aggarwal A, Loscalzao S et al.. “Pearls & Oy-sters: Severe Myotonic Crisis Resembling Malignant Hyperthermia.” Neurology (2025). PMID: 40127393 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup, Special Populations and Pregnancy
  100. [100]

    Kido K, Miyoshi H, Ikeda T et al.. “Evaluation of clinically relevant sevoflurane concentrations in the development of malignant hyperthermia in an Ryr1 mutant mouse model.” BMC anesthesiology (2026). PMID: 41877010 ↗

    L5OTHERCited in: Diagnosis and Workup
  101. [101]

    Rossi D, Pranzo C, Roccabianca S et al.. “Identification of novel potentially causative RYR1 variants in individuals with malignant hyperthermia susceptibility.” Neuromuscular disorders : NMD (2025). PMID: 41418732 ↗

    L4OTHERCited in: Diagnosis and Workup
  102. [102]

    Carpenter D, Robinson RL, Quinnell RJ et al.. “Genetic variation in RYR1 and malignant hyperthermia phenotypes.” British journal of anaesthesia (2009). PMID: 19648156 ↗

    L2OTHERCited in: Severity, Staging and Perioperative Risk Stratification
  103. [103]

    Schiemann AH, Dürholt EM, Pollock N et al.. “Sequence capture and massively parallel sequencing to detect mutations associated with malignant hyperthermia.” British journal of anaesthesia (2012). PMID: 23035052 ↗

    L4OTHERCited in: Severity, Staging and Perioperative Risk Stratification, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  104. [104]

    Duke AM, Hopkins PM, Halsall PJ et al.. “Mg2+ dependence of Ca2+ release from the sarcoplasmic reticulum induced by sevoflurane or halothane in skeletal muscle from humans susceptible to malignant hyperthermia.” British journal of anaesthesia (2006). PMID: 16849381 ↗

    L3OTHERCited in: Severity, Staging and Perioperative Risk Stratification
  105. [105]

    Lavezzi WA, Capacchione JF, Muldoon SM et al.. “Case report: Death in the emergency department: an unrecognized awake malignant hyperthermia-like reaction in a six-year-old.” Anesthesia and analgesia (2012). PMID: 23267001 ↗

    L4CASE_REPORTCited in: Severity, Staging and Perioperative Risk Stratification, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  106. [106]

    Chen PL, Chang YW, Chen CY et al.. “Novel variants near the central domain of RYR1 in two malignant hyperthermia-susceptible families from Taiwan.” Anesthesia and analgesia (2009). PMID: 19762757 ↗

    L4CASE_REPORTCited in: Severity, Staging and Perioperative Risk Stratification
  107. [107]

    Metterlein T, Zink W, Kranke E et al.. “Cardiopulmonary bypass in malignant hyperthermia susceptible patients: a systematic review of published cases.” The Journal of thoracic and cardiovascular surgery (2011). PMID: 21376345 ↗

    L4SR_OBSCited in: Severity, Staging and Perioperative Risk Stratification, Prognosis and Natural History
  108. [108]

    Dexter F, Epstein RH, Wachtel RE et al.. “Estimate of the relative risk of succinylcholine for triggering malignant hyperthermia.” Anesthesia and analgesia (2012). PMID: 23223104 ↗

    L2OTHERCited in: Severity, Staging and Perioperative Risk Stratification
  109. [109]

    Joshi GP, Desai MS, Gayer S et al.. “Succinylcholine for Emergency Airway Rescue in Class B Ambulatory Facilities: The Society for Ambulatory Anesthesia Position Statement.” Anesthesia and analgesia (2017). PMID: 27984222 ↗

    L5OTHERCited in: Severity, Staging and Perioperative Risk Stratification, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, Acute Management and Crisis Pathways
  110. [110]

    Neira VM, Al Madhoun W, Ghaffari K et al.. “Efficacy of Malignant Hyperthermia Association of the United States-Recommended Methods of Preparation for Malignant Hyperthermia-Susceptible Patients Using Dräger Zeus Anesthesia Workstations and Associated Costs.” Anesthesia and analgesia (2019). PMID: 29847377 ↗

    L5OTHERCited in: Severity, Staging and Perioperative Risk Stratification, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  111. [111]

    Lew A, Morrison JM, Amankwah EK et al.. “Volatile anesthetic agents for life-threatening pediatric asthma: A multicenter retrospective cohort study and narrative review.” Paediatric anaesthesia (2021). PMID: 34514673 ↗

    L2COHORTCited in: Severity, Staging and Perioperative Risk Stratification, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, Acute Management and Crisis Pathways, Special Populations and Pregnancy
  112. [112]

    van den Bersselaar LR, Kruijt N, Scheffer GJ et al.. “The neuromuscular and multisystem features of RYR1-related malignant hyperthermia and rhabdomyolysis: A study protocol.” Medicine (2021). PMID: 34414986 ↗

    L5TRIAL_NONRANDOMCited in: Severity, Staging and Perioperative Risk Stratification
  113. [113]

    Bezak BJ, Arce KA, Jacob A et al.. “Orthognathic Surgery in Patients With Congenital Myopathies and Congenital Muscular Dystrophies: Case Series and Review of the Literature.” Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons (2015). PMID: 26292175 ↗

    L4CASE_REPORTCited in: Severity, Staging and Perioperative Risk Stratification, Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  114. [114]

    Forrest KM, Foulds N, Millar JS et al.. “RYR1-related malignant hyperthermia with marked cerebellar involvement - a paradigm of heat-induced CNS injury?” Neuromuscular disorders : NMD (2014). PMID: 25466363 ↗

    L4CASE_REPORTCited in: Severity, Staging and Perioperative Risk Stratification
  115. [115]

    Crawford MW, Prinzhausen H, Petroz GC. “Accelerating the washout of inhalational anesthetics from the Dräger Primus anesthetic workstation: effect of exchangeable internal components.” Anesthesiology (2007). PMID: 17264723 ↗

    L5OTHERCited in: Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  116. [116]

    Foster RN, Boothroyd KP. “Caesarean section in a complicated case of central core disease.” Anaesthesia (2008). PMID: 18412656 ↗

    L4CASE_REPORTCited in: Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, Regional and Interventional Procedures, Special Populations and Pregnancy
  117. [117]

    Kaufmann A, Kraft B, Michalek-Sauberer A et al.. “Novel double and single ryanodine receptor 1 variants in two Austrian malignant hyperthermia families.” Anesthesia and analgesia (2012). PMID: 22415532 ↗

    L4CASE_REPORTCited in: Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  118. [118]

    Kwetny I, Finucane BT. “Negative arterial to end-tidal carbon dioxide gradient: an additional sign of malignant hyperthermia during desflurane anesthesia.” Anesthesia and analgesia (2006). PMID: 16492834 ↗

    L4CASE_REPORTCited in: Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  119. [119]

    Capacchione JF, Radimer MC, Sagel JS et al.. “Trauma, systemic inflammatory response syndrome, dietary supplements, illicit steroid use and a questionable malignant hyperthermia reaction.” Anesthesia and analgesia (2009). PMID: 19224800 ↗

    L4CASE_REPORTCited in: Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, History and Evolution of Treatment
  120. [120]

    Cottron N, Larcher C, Sommet A et al.. “The sevoflurane washout profile of seven recent anesthesia workstations for malignant hyperthermia-susceptible adults and infants: a bench test study.” Anesthesia and analgesia (2014). PMID: 24806140 ↗

    L5OTHERCited in: Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  121. [121]

    Manser T, Harrison TK, Gaba DM et al.. “Coordination patterns related to high clinical performance in a simulated anesthetic crisis.” Anesthesia and analgesia (2009). PMID: 19372344 ↗

    L5OTHERCited in: Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  122. [122]

    Birgenheier N, Stoker R, Westenskow D et al.. “Activated charcoal effectively removes inhaled anesthetics from modern anesthesia machines.” Anesthesia and analgesia (2011). PMID: 21543783 ↗

    L5OTHERCited in: Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  123. [123]

    Tageldin T, Khan MJ, Baykuziyev T et al.. “Intraoperative tourniquet-induced hyperthermia in a pediatric patient: a forgotten association -a case report.” Korean journal of anesthesiology (2024). PMID: 38171593 ↗

    L4CASE_REPORTCited in: Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, Acute Management and Crisis Pathways
  124. [124]

    Li J, Bao J, Zhang D et al.. “Case report: Spinal anesthesia for cesarean section in a parturient with Potocki-Lupski syndrome.” BMC anesthesiology (2021). PMID: 34493221 ↗

    L4CASE_REPORTCited in: Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, Regional and Interventional Procedures
  125. [125]

    Pepper MB, Njathi-Ori C, Kinney MO. “Don't stress: a case report of regional anesthesia as the primary anesthetic for gynecologic surgery in a patient with mitochondrial myopathy and possible malignant hyperthermia susceptibility.” BMC anesthesiology (2019). PMID: 31837701 ↗

    L4CASE_REPORTCited in: Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care, Regional and Interventional Procedures
  126. [126]

    Gibbs IC, Fadahunsi O, Reid N et al.. “Malignant Hyperthermia: A Case Report in a Trauma Patient.” Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons (2018). PMID: 30098954 ↗

    L4CASE_REPORTCited in: Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  127. [127]

    Thoben C, Dennhardt N, Krauß T et al.. “Preparation of anaesthesia workstation for trigger-free anaesthesia: An observational laboratory study.” European journal of anaesthesiology (2019). PMID: 31580288 ↗

    L5OTHERCited in: Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  128. [128]

    Jones PM, Allen BN, Cherry RA et al.. “Association between known or strongly suspected malignant hyperthermia susceptibility and postoperative outcomes: an observational population-based study.” Canadian journal of anaesthesia = Journal canadien d'anesthesie (2018). PMID: 30421146 ↗

    L2OTHERCited in: Perioperative Anesthetic Conduct: Airway Management, Technique Selection and Intraoperative Care
  129. [129]

    Marshall S. “The use of cognitive aids during emergencies in anesthesia: a review of the literature.” Anesthesia and analgesia (2013). PMID: 24029855 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Crisis Pathways
  130. [130]

    Wiesmann T, Freitag D, Dersch W et al.. “Dantrolene versus amiodarone for cardiopulmonary resuscitation: a randomized, double-blinded experimental study.” Scientific reports (2017). PMID: 28098197 ↗

    L5RCTCited in: Acute Management and Crisis Pathways, Multimodal Analgesia Ladder and Long-term Pharmacotherapy
  131. [131]

    Bamaga AK, Riazi S, Amburgey K et al.. “Neuromuscular conditions associated with malignant hyperthermia in paediatric patients: A 25-year retrospective study.” Neuromuscular disorders : NMD (2016). PMID: 26951757 ↗

    L4COHORTCited in: Acute Management and Crisis Pathways
  132. [132]

    Erbele I, Chapman E, Wilson MN et al.. “Malignant Hyperthermia During Translabyrinthine Acoustic Neuroma Surgery After Previous Uneventful Surgery.” Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology (2019). PMID: 31157728 ↗

    L4CASE_REPORTCited in: Acute Management and Crisis Pathways
  133. [133]

    Zvaritch E, Gillies R, Kraeva N et al.. “Fatal awake malignant hyperthermia episodes in a family with malignant hyperthermia susceptibility: a case series.” Canadian journal of anaesthesia = Journal canadien d'anesthesie (2019). PMID: 30805902 ↗

    L4CASE_REPORTCited in: Acute Management and Crisis Pathways
  134. [134]

    Urwyler A, Deufel T, McCarthy T et al.. “Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia.” British journal of anaesthesia (2001). PMID: 11573677 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  135. [135]

    Larach MG, Dirksen SJ, Belani KG et al.. “Special article: Creation of a guide for the transfer of care of the malignant hyperthermia patient from ambulatory surgery centers to receiving hospital facilities.” Anesthesia and analgesia (2011). PMID: 22052978 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  136. [136]

    Chopra V, Gesink BJ, de Jong J et al.. “Does training on an anaesthesia simulator lead to improvement in performance?” British journal of anaesthesia (1994). PMID: 7946851 ↗

    L1RCTCited in: History and Evolution of Treatment
  137. [137]

    Larach MG, Landis JR, Bunn JS et al.. “Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. The North American Malignant Hyperthermia Registry.” Anesthesiology (1992). PMID: 1729931 ↗

    L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  138. [138]

    Reber A, Schumacher P, Urwyler A. “Effects of three different types of management on the elimination kinetics of volatile anaesthetics. Implications for malignant hyperthermia treatment.” Anaesthesia (1993). PMID: 8238827 ↗

    L1RCTCited in: History and Evolution of Treatment
  139. [139]

    Berkenstadt H, Yusim Y, Ziv A et al.. “An assessment of a point-of-care information system for the anesthesia provider in simulated malignant hyperthermia crisis.” Anesthesia and analgesia (2006). PMID: 16428555 ↗

    L2RCTCited in: History and Evolution of Treatment, Multimodal Analgesia Ladder and Long-term Pharmacotherapy
  140. [140]

    Ibarra Moreno CA, Kraeva N, Zvaritch E et al.. “Oral Dantrolene for Myopathic Symptoms in Malignant Hyperthermia-Susceptible Patients: A 25-Year Retrospective Cohort Study of Adverse Effects and Tolerability.” Anesthesia and analgesia (2022). PMID: 36201369 ↗

    L2COHORTCited in: History and Evolution of Treatment
  141. [141]

    Larach MG, Localio AR, Allen GC et al.. “A clinical grading scale to predict malignant hyperthermia susceptibility.” Anesthesiology (1994). PMID: 8024130 ↗

    L5CASE_REPORTCited in: History and Evolution of Treatment
  142. [142]

    Ibarra Moreno CA, Kraeva N, Zvaritch E et al.. “A multi-dimensional analysis of genotype-phenotype discordance in malignant hyperthermia susceptibility.” British journal of anaesthesia (2020). PMID: 32861507 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  143. [143]

    O'Donnell CJ, Beck DH, Taylor BL et al.. “Upper limb compartment syndromes: a complication of malignant hyperthermia in a patient with ill-defined myopathy.” British journal of anaesthesia (1995). PMID: 7718387 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  144. [144]

    Strazis KP, Fox AW. “Malignant hyperthermia: a review of published cases.” Anesthesia and analgesia (1993). PMID: 8346828 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  145. [145]

    van den Bersselaar LR, Hellblom A, Gashi M et al.. “Referral Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing.” Anesthesiology (2022). PMID: 35285867 ↗

    L2OTHERCited in: History and Evolution of Treatment
  146. [146]

    O'Flynn RP, Shutack JG, Rosenberg H et al.. “Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis.” Anesthesiology (1994). PMID: 8010468 ↗

    L4OTHERCited in: History and Evolution of Treatment
  147. [147]

    Fiege M, Wappler F, Weisshorn R et al.. “Induction of malignant hyperthermia in susceptible swine by 3,4-methylenedioxymethamphetamine ("ecstasy").” Anesthesiology (2003). PMID: 14576550 ↗

    L5OTHERCited in: History and Evolution of Treatment
  148. [148]

    Larach MG, Brandom BW, Allen GC et al.. “Cardiac arrests and deaths associated with malignant hyperthermia in north america from 1987 to 2006: a report from the north american malignant hyperthermia registry of the malignant hyperthermia association of the United States.” Anesthesiology (2008). PMID: 18362591 ↗

    L4OTHERCited in: History and Evolution of Treatment, Special Populations and Pregnancy
  149. [149]

    Wappler F, Fiege M, Steinfath M et al.. “Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis.” Anesthesiology (2001). PMID: 11135728 ↗

    L3OTHERCited in: History and Evolution of Treatment
  150. [150]

    Fletcher JE, Rosenberg H. “In vitro interaction between halothane and succinylcholine in human skeletal muscle: implications for malignant hyperthermia and masseter muscle rigidity.” Anesthesiology (1985). PMID: 4025868 ↗

    L5OTHERCited in: History and Evolution of Treatment
  151. [151]

    Pollock NA, Machon RG, Rosenberg H. “Early Development, Identification of Mode of Action, and Use of Dantrolene Sodium: The Role of Keith Ellis, Ph.D.” Anesthesiology (2017). PMID: 28272142 ↗

    L5OTHERCited in: History and Evolution of Treatment
  152. [152]

    White R, Schiemann AH, Burling SM et al.. “Functional analysis of RYR1 variants in patients with confirmed susceptibility to malignant hyperthermia.” British journal of anaesthesia (2022). PMID: 36208971 ↗

    L4OTHERCited in: History and Evolution of Treatment
  153. [153]

    Whittaker M, Britten JJ. “Malignant hyperthermia and the fluoride-resistant gene.” British journal of anaesthesia (1981). PMID: 7470359 ↗

    L4OTHERCited in: History and Evolution of Treatment
  154. [154]

    Laurence AS, Vanner GK, Collins W et al.. “Serum and urinary myoglobin following an aborted malignant hyperthermia reaction.” Anaesthesia (1996). PMID: 8984872 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  155. [155]

    Yu Y, Zhou Y, Zhang Y et al.. “Beyond Hotspots: Functional Characterization of the Novel p.Asp2730Tyr Mutation in RYR1 Associated With Malignant Hyperthermia.” Anesthesia and analgesia (2025). PMID: 40408285 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment, Complications
  156. [156]

    Lichtman AD, Oribabor C. “Malignant hyperthermia following systemic rewarming after hypothermic cardiopulmonary bypass.” Anesthesia and analgesia (2006). PMID: 16428525 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  157. [157]

    Ng Kwet Shing RH, Clayton LB, Smith SL et al.. “The novel rapid formulation of intravenous dantrolene (NPJ5008) versus standard dantrolene (Dantrium®): A clinical part-randomised phase 1 study in healthy volunteers.” European journal of anaesthesiology (2024). PMID: 38445365 ↗

    L1RCTCited in: History and Evolution of Treatment, Multimodal Analgesia Ladder and Long-term Pharmacotherapy, Special Populations and Pregnancy
  158. [158]

    Harrison GG, Isaacs H. “Malignant hyperthermia. An historical vignette.” Anaesthesia (1992). PMID: 1536407 ↗

    L5OTHERCited in: History and Evolution of Treatment
  159. [159]

    Rosenberg H, Fletcher JE. “Masseter muscle rigidity and malignant hyperthermia susceptibility.” Anesthesia and analgesia (1986). PMID: 3942303 ↗

    L4OTHERCited in: History and Evolution of Treatment
  160. [160]

    Dave M, Shore R, Cupido T et al.. “Anaesthetic implications of psilocybin and lysergic acid diethylamide: what is old is now new: A narrative review on psychedelics and anaesthesia.” European journal of anaesthesiology (2025). PMID: 39967455 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  161. [161]

    Wilson JP, Bonin B, Quinones C et al.. “Spinal Anesthesia for Awake Spine Surgery: A Paradigm Shift for Enhanced Recovery after Surgery.” Journal of clinical medicine (2024). PMID: 39274539 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  162. [162]

    Shear TD, Deshur M, Benson J et al.. “The Effect of an Electronic Dynamic Cognitive Aid Versus a Static Cognitive Aid on the Management of a Simulated Crisis: A Randomized Controlled Trial.” Journal of medical systems (2018). PMID: 30467609 ↗

    L1RCTCited in: Multimodal Analgesia Ladder and Long-term Pharmacotherapy
  163. [163]

    Tian X, Liu Y, Wang M et al.. “[A systematic review of adenoidectomy in the treatment of otitis media with effusion in children].” Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery (2014). PMID: 26248446 ↗

    L1SR_OBSCited in: Multimodal Analgesia Ladder and Long-term Pharmacotherapy
  164. [164]

    Lu Z, Huang M, Liu L et al.. “Drug-induced perioperative malignant hyperthermia: a real-world study based on the Food and Drug Administration Adverse Event Reporting System (FAERS) database.” International journal of surgery (London, England) (2025). PMID: 41731858 ↗

    L4OTHERCited in: Multimodal Analgesia Ladder and Long-term Pharmacotherapy
  165. [165]

    do Carmo PL, Zapata-Sudo G, Trachez MM et al.. “Intravenous administration of azumolene to reverse malignant hyperthermia in swine.” Journal of veterinary internal medicine (2010). PMID: 20584138 ↗

    L5OTHERCited in: Multimodal Analgesia Ladder and Long-term Pharmacotherapy
  166. [166]

    Rodgers A, Cox RG. “Anesthetic management for pediatric strabismus surgery: Continuing professional development.” Canadian journal of anaesthesia = Journal canadien d'anesthesie (2010). PMID: 20393822 ↗

    L5OTHERCited in: Multimodal Analgesia Ladder and Long-term Pharmacotherapy
  167. [167]

    Brackmann F, Türk M, Gratzki N et al.. “Compound heterozygous RYR1 mutations in a preterm with arthrogryposis multiplex congenita and prenatal CNS bleeding.” Neuromuscular disorders : NMD (2017). PMID: 29169929 ↗

    L4CASE_REPORTCited in: Regional and Interventional Procedures
  168. [168]

    Klaska C, Gonik B. “Obstetric outcome in a primigravid patient with autosomal-recessive multiminicore myopathy.” Obstetrics and gynecology (2014). PMID: 24413229 ↗

    L4CASE_REPORTCited in: Regional and Interventional Procedures, Prognosis and Natural History
  169. [169]

    Burke S, Hanani M. “The actions of hyperthermia on the autonomic nervous system: central and peripheral mechanisms and clinical implications.” Autonomic neuroscience : basic & clinical (2012). PMID: 22426078 ↗

    L5REVIEW_NARRATIVECited in: Regional and Interventional Procedures
  170. [170]

    Riley J, Butler J, Baker KB et al.. “Targeted spinal cord therapeutics delivery: stabilized platform and microelectrode recording guidance validation.” Stereotactic and functional neurosurgery (2007). PMID: 18073518 ↗

    L5OTHERCited in: Regional and Interventional Procedures
  171. [171]

    Yonekawa Y, Wu WC, Kusaka S et al.. “Immediate Sequential Bilateral Pediatric Vitreoretinal Surgery: An International Multicenter Study.” Ophthalmology (2016). PMID: 27221737 ↗

    L4OTHERCited in: Regional and Interventional Procedures
  172. [172]

    Leite AI, Ramos SDS, In Cio R et al.. “Several challenges associated with the anesthetic management of Emery-Dreifuss muscular dystrophy patients: case report.” Brazilian journal of anesthesiology (Elsevier) (2021). PMID: 34624368 ↗

    L4CASE_REPORTCited in: Regional and Interventional Procedures
  173. [173]

    Inoue M, Morita M. “Total intravenous anesthesia using midazolam and dexmedetomidine as substitutes for propofol in a pediatric patient with egg allergy and a family history of malignant hyperthermia.” Saudi journal of anaesthesia (2024). PMID: 39600453 ↗

    L4CASE_REPORTCited in: Regional and Interventional Procedures
  174. [174]

    Erdoğan MA, Sanli M, Ersoy MO. “Anesthesia management in a child with osteogenesis imperfecta and epidural hemorrhage.” Brazilian journal of anesthesiology (Elsevier) (2013). PMID: 24565246 ↗

    L4CASE_REPORTCited in: Regional and Interventional Procedures
  175. [175]

    Erdoğan MA, Sanli M, Ersoy MO. “Anesthesia management in a child with osteogenesis imperfecta and epidural hemorrhage.” Brazilian journal of anesthesiology (Elsevier) (2013). PMID: 23931253 ↗

    L4CASE_REPORTCited in: Regional and Interventional Procedures
  176. [176]

    Vassiliadis RM. “Anaesthetic management of a parturient with hypokalaemic periodic paralysis for caesarean section: A case report and review of the literature.” Anaesthesia and intensive care (2024). PMID: 38879798 ↗

    L4CASE_REPORTCited in: Regional and Interventional Procedures
  177. [177]

    Pinto LDC, Silva CHRD, Gonçalves PMSE et al.. “[Supraclavicular nerve and superior trunk block for surgical treatment of clavicle fracture in a patient with Steinert's disease - Case report].” Brazilian journal of anesthesiology (Elsevier) (2018). PMID: 30301614 ↗

    L4CASE_REPORTCited in: Regional and Interventional Procedures
  178. [178]

    Ramanujam V, Hoffman CR, Russo K et al.. “[Acute postoperative sepsis mimicking symptomology suspicious for malignant hyperthermia: case report].” Brazilian journal of anesthesiology (Elsevier) (2019). PMID: 31784196 ↗

    L4CASE_REPORTCited in: Regional and Interventional Procedures
  179. [179]

    Joseph TT, Bu W, Haji-Ghassemi O et al.. “Propofol binds and inhibits skeletal muscle ryanodine receptor 1.” British journal of anaesthesia (2024). PMID: 39304470 ↗

    L5OTHERCited in: Complications
  180. [180]

    Visoiu M, Young MC, Wieland K et al.. “Anesthetic drugs and onset of malignant hyperthermia.” Anesthesia and analgesia (2014). PMID: 24445637 ↗

    L2OTHERCited in: Complications, Special Populations and Pregnancy
  181. [181]

    Pu Y, Su Y, Li L et al.. “Cesarean delivery in a patient with inclusion body myositis: is general anesthesia safe? A case report.” Frontiers in medicine (2026). PMID: 42266941 ↗

    L4CASE_REPORTCited in: Complications
  182. [182]

    Zhu K, Wu S, Hao X et al.. “Successful sedation with remimazolam and alfentanil in a child susceptible to malignant hyperthermia: a case report.” BMC anesthesiology (2025). PMID: 40269725 ↗

    L4CASE_REPORTCited in: Complications
  183. [183]

    Illingworth MA, Main M, Pitt M et al.. “RYR1-related congenital myopathy with fatigable weakness, responding to pyridostigimine.” Neuromuscular disorders : NMD (2014). PMID: 24951453 ↗

    L4CASE_REPORTCited in: Prognosis and Natural History
  184. [184]

    Imagama S, Kawakami N, Tsuji T et al.. “Kyphoscoliosis associated with congenital neuromuscular disease with uniform type 1 fibers.” European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (2011). PMID: 22193842 ↗

    L4CASE_REPORTCited in: Prognosis and Natural History
  185. [185]

    Jungbluth H, Lillis S, Zhou H et al.. “Late-onset axial myopathy with cores due to a novel heterozygous dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene.” Neuromuscular disorders : NMD (2009). PMID: 19303294 ↗

    L4CASE_REPORTCited in: Prognosis and Natural History
  186. [186]

    Kilbane BJ, Mehta S, Backeljauw PF et al.. “Approach to management of malignant hyperthermia-like syndrome in pediatric diabetes mellitus.” Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies (2006). PMID: 16531950 ↗

    L4CASE_REPORTCited in: Prognosis and Natural History
  187. [187]

    Litman RS, Flood CD, Kaplan RF et al.. “Postoperative malignant hyperthermia: an analysis of cases from the North American Malignant Hyperthermia Registry.” Anesthesiology (2008). PMID: 18946294 ↗

    L2OTHERCited in: Special Populations and Pregnancy
  188. [188]

    Broman M, Gehrig A, Islander G et al.. “Mutation screening of the RYR1-cDNA from peripheral B-lymphocytes in 15 Swedish malignant hyperthermia index cases.” British journal of anaesthesia (2009). PMID: 19346234 ↗

    L4OTHERCited in: Special Populations and Pregnancy
  189. [189]

    Hogan KJ, Vladutiu GD. “Malignant hyperthermia-like syndrome and carnitine palmitoyltransferase II deficiency with heterozygous R503C mutation.” Anesthesia and analgesia (2009). PMID: 19762733 ↗

    L4CASE_REPORTCited in: Special Populations and Pregnancy
  190. [190]

    Larach MG, Gronert GA, Allen GC et al.. “Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006.” Anesthesia and analgesia (2010). PMID: 20081135 ↗

    L2OTHERCited in: Special Populations and Pregnancy
  191. [191]

    Garavatti E, Peretz RH, Cruz C et al.. “Neurodevelopmental Symptoms Associated With MIRAGE Syndrome: A Case Report of Three Children and Review of the Literature.” Pediatric neurology (2026). PMID: 41962271 ↗

    L4CASE_REPORTCited in: Special Populations and Pregnancy
  192. [192]

    Zdravkova I, Tilkiyan E, Ivanov H et al.. “Acute Kidney Injury and Chronic Kidney Disease Associated with a Genetic Defect: A Report of Two Cases.” International journal of molecular sciences (2025). PMID: 40429823 ↗

    L4CASE_REPORTCited in: Special Populations and Pregnancy
  193. [193]

    Janßen S, Erbe LS, Kneifel M et al.. “Compound Heterozygous RYR1 Variants in a Patient with Severe Congenital Myopathy: Case Report and Comparison with Additional Cases of Recessive RYR1-Related Myopathy.” International journal of molecular sciences (2024). PMID: 39409197 ↗

    L4CASE_REPORTCited in: Special Populations and Pregnancy
  194. [194]

    Nakano M, Funayama M, Takata T et al.. “Caution for psychiatrists: malignant hyperthermia risks with the anesthetic agent succinylcholine (Suxamethonium) during electroconvulsive therapy.” BMC psychiatry (2024). PMID: 38834964 ↗

    L4CASE_REPORTCited in: Special Populations and Pregnancy
  195. [195]

    Famili DT, Mistry A, Gerasimenko O et al.. “Pancreatitis in RYR1-related disorders.” Neuromuscular disorders : NMD (2023). PMID: 37783627 ↗

    L4OTHERCited in: Prevention, Screening and Surveillance

Revision History

All updates applied to this page

Loading revisions…